NasdaqGS - Delayed Quote USD

HilleVax, Inc. (HLVX)

12.79 +0.77 (+6.41%)
At close: April 26 at 4:00 PM EDT
12.79 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Robert M. Hershberg M.D., Ph.D. President, CEO & Chairman of the Board 1.02M -- 1962
Dr. Aditya Kohli Ph.D. Chief Business Officer & Director 782.44k -- 1989
Mr. Shane A. Maltbie CFO & Treasurer -- -- 1982
Mr. Sean McLoughlin Chief Operating Officer -- -- 1972
Dr. Anju Chatterji Ph.D. Chief Technology Officer -- -- --
Mr. Paul S. Bavier J.D. General Counsel, Secretary & Chief Administrative Officer -- -- 1972
Ms. Astrid Borkowski M.D., Ph.D. Chief Medical Officer -- -- 1970
Mr. Ozzie Berger Senior Vice President of Regulatory Affairs -- -- --

HilleVax, Inc.

321 Harrison Avenue
5th floor
Boston, MA 02118
United States
617 213 5054 https://www.hillevax.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
90

Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Corporate Governance

HilleVax, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 7; Board: 10; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

ANRO Alto Neuroscience, Inc.
14.18
+0.35%
 
VALN Valneva SE
7.64
+1.32%
 
TYRA Tyra Biosciences, Inc.
15.67
+3.71%
 
LXEO Lexeo Therapeutics, Inc.
12.50
+2.80%
 
AVTE Aerovate Therapeutics, Inc.
21.75
+0.83%
 
THRD Third Harmonic Bio, Inc.
10.83
+3.54%
 
688428.SS InnoCare Pharma Limited
8.32
+2.21%
 
NB11.F Vaxart, Inc.
0.6335
-3.06%
 
NGNE Neurogene Inc.
29.96
+0.30%
 
ANAB AnaptysBio, Inc.
21.00
+11.29%